US81663L2007
© BusinessWire
15.12.2025
WGS
LISTED
NASDAQ
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
WGS
LISTED
NASDAQ
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
“GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-rea...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
WGS
LISTED
NASDAQ
GeneDx to Participate in Upcoming Investor Conferences
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel 2025 Healthcare Conference
New York, New York
Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET
Jefferies Global Healthcare Conference
Lo...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
28.10.2025
WGS
LISTED
NASDAQ
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025.
“GeneDx’s accelerated growth reflects more than business momentum - it’s proof of the profound impact we’re making for families navigating rare disease and the broader...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
24.10.2025
WGS
LISTED
NASDAQ
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.
If you currently own GeneDx stock and acquired shares on or before January 18, 2022, you may be able to seek corporate governance reforms, the return of fun...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
WGS
LISTED
NASDAQ
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at the International Consortium on Newborn Sequencing (ICoNS), underscoring the company’s leadership in driving genomic newborn screening (gNBS) from research into real-world clinical implementation.
As the labor...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
WGS
LISTED
NASDAQ
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
WGS
LISTED
NASDAQ
GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life.
As Chief Precision Medicine Officer, Dr. Lee will lead...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
WGS
LISTED
NASDAQ
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program.
The S...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
WGS
LISTED
NASDAQ
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the foundin...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
WGS
LISTED
NASDAQ
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.
At ASHG, GeneDx will unveil research findings drawn from GeneDx Infinity™, a dataset of nearly one million exom...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
WGS
LISTED
NASDAQ
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. Management will host a conference call that day to discuss third quarter 2025 financial and operating results at 8:30 a...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
01.10.2025
WGS
LISTED
NASDAQ
GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, alongside Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina, today announc...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
WGS
LISTED
NASDAQ
GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health sys...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
WGS
LISTED
NASDAQ
GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx’s Infinity, the company’s proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition taking place this weekend September 26 to 30 in Denver, CO. Infinit...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
WGS
LISTED
NASDAQ
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors.
“With the world’s largest rare disease data set, we’re only beginning to realize AI’s full potential to deliver faster, more...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
WGS
LISTED
NASDAQ
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.
“Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
WGS
LISTED
NASDAQ
GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a....
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
WGS
LISTED
NASDAQ
GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children’s supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for no...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
WGS
LISTED
NASDAQ
GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
WGS
LISTED
NASDAQ
Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases
News Preview
Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.
The initial offering will include an inherited cardiovascular gene panel based on Amer...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
WGS
LISTED
NASDAQ
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
So What: If you purchased GeneDx securities y...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
WGS
LISTED
NASDAQ
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of the securities laws.
The investigation focuses on whether GeneDx issued false and/or misleading statements and/or failed to discl...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
WGS
LISTED
NASDAQ
GeneDx to Participate in Upcoming Investor Conferences
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Jefferies Global Healthcare Conference – June 4, 2025
New York City, New York
Fireside chat on Wednesday, June 4 at 9:55 a.m. ET
Goldman Sachs 46th Annual Gl...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
WGS
LISTED
NASDAQ
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in the American Journal of Medical Genetics, demonstrating GeneDx’s leadership in applying artificial intelligence (AI) to accelerate and enhance genetic diagnostics. The article was published as part of...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
WGS
LISTED
NASDAQ
GeneDx Announces Completion of Fabric Genomics Acquisition
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powere...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
WGS
LISTED
NASDAQ
GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025.
“Healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential – both for better clinical outcomes and for saving the...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
WGS
LISTED
NASDAQ
GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction enables GeneDx’s leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence.
“Healthcare is...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
WGS
LISTED
NASDAQ
GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
WGS
LISTED
NASDAQ
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of Immunity (IEI), a group of nearly 500 genetic disorders that impair immune function2, increasing susceptibility to infections, autoimmunity, and inflammatory conditions. The strategic expans...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
WGS
LISTED
NASDAQ
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15, 2025, the compensation committee of GeneDx’s board of directors granted 46,340 restricted stock units (“RSUs”) to ten newly-hired employees as inducements material to each employee entering into employment...
Themefolio
Profiler
Peergroup
© BusinessWire
18.03.2025
WGS
LISTED
NASDAQ
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category. This year’s list shines a spotlight on businesses that are shaping industry an...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
WGS
LISTED
NASDAQ
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights. Multiscore is embedded into GeneDx’s interpr...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
WGS
LISTED
NASDAQ
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. GeneDx will showcase its leadership in genomic research and innovation, driving the ind...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
WGS
LISTED
NASDAQ
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its industry leading genetic testing to now include cerebral palsy (CP). In conjunction with Cerebral Palsy Awareness Month, the company is expanding its strategy of focusing on pediatric rare disease patients...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
WGS
LISTED
NASDAQ
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study conducted in partnership with Seattle Children’s and the University of Washington. Seqfirst-neo is a pioneering study focused on the...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
WGS
LISTED
NASDAQ
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024.
"The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading e...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
WGS
LISTED
NASDAQ
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced ultraRapid Whole Genome Sequencing, offering accelerated and comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 2 days.
ultraRapid genome testing delivers a faster diagnosis, providing...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
WGS
LISTED
NASDAQ
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA. Management will participate in a fireside chat on Tuesday, March 4, 2025, at 1:10 p.m. ET.
A live and archived we...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
WGS
LISTED
NASDAQ
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics suite, offering advance genetic sequencing within health systems electronic health records (EHR) to receive orders and send results. GeneDx is expanding access to its industry leading diag...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
WGS
LISTED
NASDAQ
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for the fourth quarter 2024 and the full year 2024 before the market opens on Tuesday, February 18, 2025. Management will host a conference call that day to discuss fourth quarter 2024 and full year 2024 finan...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
WGS
LISTED
NASDAQ
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025, the compensation committee of GeneDx’s board of directors granted a total of 69,089 restricted stock units (“RSUs”) to three newly-hired employees as inducements material to each emp...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
WGS
LISTED
NASDAQ
GeneDx Announces Preliminary 2024 Financial Results
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2024.
“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengt...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
WGS
LISTED
NASDAQ
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and test-ordering services for patients and families seeking access to genetic testing. The new telehealth testing pathway aims to shorten the diagnostic odyssey by connecting parents directly with...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
WGS
LISTED
NASDAQ
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through understanding gene-disease relationships, contributing to more than 85 peer-reviewed publications in 2024. These contributions, added to GeneDx’s years of dedicated research efforts, inf...
Themefolio
Profiler
Peergroup
© BusinessWire
02.01.2025
WGS
LISTED
NASDAQ
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company’s executive leadership team.
As C...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
WGS
LISTED
NASDAQ
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT.
Live...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
WGS
LISTED
NASDAQ
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke Therapeutics (Nasdaq: STOK) as the founding partners to its Patient Access Program for pediatric epilepsy, which provides access to whole exome sequencing.
Curr...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
WGS
LISTED
NASDAQ
GeneDx to Participate in Upcoming Investor Conference
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET.
Live...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
WGS
LISTED
NASDAQ
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx’s robust database - to improve all stages of drug development...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
WGS
LISTED
NASDAQ
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team.
With over 30 years of experien...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
WGS
LISTED
NASDAQ
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Pr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
WGS
LISTED
NASDAQ
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives co...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
WGS
LISTED
NASDAQ
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
News Preview
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024.
“We delivered 77% growth on exome and genome revenues in Q3 and have reached the point of profitability, a significant milestone in our company’s history,” said Katherin...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
WGS
LISTED
NASDAQ
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
WGS
LISTED
NASDAQ
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to ex...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
WGS
LISTED
NASDAQ
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024. Management will host a conference call that day to discuss third quarter 2024 financial and operating results at 8:30 a...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
WGS
LISTED
NASDAQ
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September 23, 2024, the compensation committee of GeneDx’s board of directors granted a total of 7,700 restricted stock units (“RSUs”) to two newly hired employees as inducements material to each employee entering i...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
WGS
LISTED
NASDAQ
GeneDx to Participate in Fall Investor Conferences
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall:
UBS Genomic Medicine Summit – August 13-14, 2024
Dana Point, California
Future of Genetic Testing - Babies and Beyond Panel on Wednesday, August 14 a...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
WGS
LISTED
NASDAQ
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024, the compensation committee of GeneDx’s board of directors granted seven newly hired employees 75,100 restricted stock units (“RSUs”) as inducements material to each employee entering into employment w...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
